Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA. Oliveras-Ferraros C, et al. Among authors: cufi s. Int J Oncol. 2010 Sep;37(3):669-78. doi: 10.3892/ijo_00000716. Int J Oncol. 2010. PMID: 20664936
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
Oliveras-Ferraros C, Cufí S, Queralt B, Vazquez-Martin A, Martin-Castillo B, de Llorens R, Bosch-Barrera J, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Among authors: cufi s. Br J Cancer. 2012 Apr 10;106(8):1406-14. doi: 10.1038/bjc.2012.103. Br J Cancer. 2012. PMID: 22491422 Free PMC article.
Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Among authors: cufi s. Biochem Biophys Res Commun. 2010 Jun 18;397(1):27-33. doi: 10.1016/j.bbrc.2010.05.041. Epub 2010 May 12. Biochem Biophys Res Commun. 2010. PMID: 20470755
Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.
Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Queralt B, Báez L, Guardeño R, Hernández-Yagüe X, Martin-Castillo B, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Among authors: cufi s. J Cell Biochem. 2011 Jan;112(1):10-29. doi: 10.1002/jcb.22952. J Cell Biochem. 2011. PMID: 21104905
Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.
Oliveras-Ferraros C, Massaguer Vall-Llovera A, Carrion Salip D, Vazquez-Martin A, Cufí S, Queralt B, Martin-Castillo B, Brunet J, de Llorens R, Menendez JA. Oliveras-Ferraros C, et al. Among authors: cufi s. Invest New Drugs. 2012 Apr;30(2):846-52. doi: 10.1007/s10637-010-9612-2. Epub 2010 Dec 16. Invest New Drugs. 2012. PMID: 21161326
Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Torres-Garcia VZ, Sauri-Nadal T, Barco SD, Lopez-Bonet E, Brunet J, Martin-Castillo B, Menendez JA. Oliveras-Ferraros C, et al. Among authors: cufi s. Biochem Biophys Res Commun. 2011 Apr 8;407(2):412-9. doi: 10.1016/j.bbrc.2011.03.039. Epub 2011 Mar 21. Biochem Biophys Res Commun. 2011. PMID: 21402055
Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3.
Oliveras-Ferraros C, Fernández-Arroyo S, Vazquez-Martin A, Lozano-Sánchez J, Cufí S, Joven J, Micol V, Fernández-Gutiérrez A, Segura-Carretero A, Menendez JA. Oliveras-Ferraros C, et al. Among authors: cufi s. Int J Oncol. 2011 Jun;38(6):1533-47. doi: 10.3892/ijo.2011.993. Epub 2011 Mar 30. Int J Oncol. 2011. PMID: 21455577
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, Lopez-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Among authors: cufi s. Int J Oncol. 2011 Dec;39(6):1455-79. doi: 10.3892/ijo.2011.1155. Epub 2011 Aug 9. Int J Oncol. 2011. PMID: 21833472
62 results